Premium
Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma
Author(s) -
Li JianRi,
Chiu KunYuan,
Ou YenChuan,
Wang ShianShiang,
Chen ChuanSu,
Yang ChengKuang,
Ho HaoChung,
Cheng ChenLi,
Yang ChiRei,
Chen ChengChe,
Wang ShuChi,
Lin ChiaYen,
Hung ShengChun,
Hsu ChiannYi,
Chen ChunJung
Publication year - 2018
Publication title -
biofactors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.204
H-Index - 94
eISSN - 1872-8081
pISSN - 0951-6433
DOI - 10.1002/biof.1460
Subject(s) - fgf19 , fgf21 , medicine , receiver operating characteristic , gastroenterology , urinary system , area under the curve , fibroblast growth factor , stage (stratigraphy) , subgroup analysis , urothelial carcinoma , urology , bladder cancer , cancer , confidence interval , biology , paleontology , receptor
Fibroblast growth factors (FGF) 19, 21, and 23 have been reported as functional factors in human metabolic diseases and malignancies. We performed a prospective survey to compare circulating FGF levels in urothelial carcinoma (UC) patients and normal controls. Between 2016 and 2017, 39 patients with UC of the urinary bladder or upper urinary tract who received surgical intervention were included. All the serum samples were obtained before surgeries. The control group included 28 healthy volunteers. Analysis of the circulating FGF19, 21, and 23 levels among all 67 subjects, as well as a subgroup analysis of the 39 UC patients were performed. The median levels of serum FGF19, 21, and 23 in the UC patients were 84.2, 505.3, and 117.6 pg/mL, respectively, which were statistically different from levels found in the healthy controls ( P = 0.015, <0.001 and < 0.001, respectively). In the subgroup analysis, the FGF19 and FGF21 levels were significantly higher in end‐stage renal disease UC patients, while FGF21 was also higher in the UC patients with cardiovascular diseases and history of recurrent UC. In the receiver operating characteristic (ROC) curve analysis, FGF19, 21, and 23 were all significant predictors of UC [area under the curve (AUC)] 0.674, P = 0.015; AUC 0.918, P < 0.001; AUC 0.897, P < 0.001, respectively). In UC patients, serum FGF19 level was significantly lower, while FGF21 and 23 were significantly higher, than respective levels in healthy controls. All three markers may serve as good predictors of UC occurrence, and FGF21 level was associated with disease recurrence. © 2018 BioFactors, 45(1):62–68, 2019